- Home
- ACHC vs ARQT Comparison
ACHC vs ARQT Comparison
Compare ACHC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHC | ARQT |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACHC | ARQT |
|---|---|---|
| Price | $31.44 | $31.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | $33.79 | ★ $38.38 |
| AVG Volume (30 Days) | 1.3M | ★ 2.2M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 0.05 | 0.03 |
| Revenue | ★ $3,312,769,000.00 | $376,072,000.00 |
| Revenue This Year | $3.48 | $43.01 |
| Revenue Next Year | $5.84 | $27.70 |
| P/E Ratio | ★ $628.40 | $1,086.83 |
| Revenue Growth | 5.04 | ★ 91.34 |
| 52 Week Low | $11.43 | $19.30 |
| 52 Week High | $35.83 | $33.30 |
Technical Indicators
Market Signals| Indicator | ACHC | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 69.97 |
| Support Level | $26.70 | $24.91 |
| Resistance Level | $32.84 | N/A |
| Average True Range (ATR) | 1.13 | 1.49 |
| MACD | 0.27 | 0.75 |
| Stochastic Oscillator | 88.20 | 85.80 |
Price Performance
Historical ComparisonAbout ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Its facilities and services are classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; CTCs; and residential treatment centers. In which Acute inpatient psychiatric facilities contribute the majority of revenue in the United States. The Company has one reportable segment, behavioral healthcare services. The behavioral healthcare services segment provides inpatient and outpatient behavioral healthcare services.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.